公开(公告)号：US20160000782A1

公开(公告)日：2016-01-07

申请号：US14769220

申请日：2014-02-14

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Hiroshi TAKASHIMA ,  Shuji IZUMO

IPC: A61K31/505 ,  A61K31/42

CPC classification number: A61K31/505 ,  A61K31/42 ,  A61K31/63 ,  A61K31/635 ,  A61K45/06 ,  A61K2300/00

Abstract: [Problem] The purpose of the present invention is to provide a pharmaceutical composition containing an antibacterial agent, which is effective in elucidating one cause of dementia, and in treatment thereof.[Solution] The present invention provides a pharmaceutical composition for treatment of dementia, containing an antibacterial agent. The present invention moreover provides a pharmaceutical composition for treatment of extreme halophile infections, containing a folic acid synthesis inhibitor.

Abstract translation: 本发明的目的是提供一种含有抗菌剂的药物组合物，其有效地阐明一种痴呆原因及其治疗方法。 [解决方案]本发明提供含有抗菌剂的治疗痴呆症的药物组合物。 本发明还提供了用于治疗极度嗜酸性细菌感染的药物组合物，其含有叶酸合成抑制剂。

公开(公告)号：US20190160067A1

公开(公告)日：2019-05-30

申请号：US16322356

申请日：2017-08-02

Applicant: Kagoshima University

Inventor： Daisuke KODAMA ,  Shuji IZUMO

IPC: A61K31/506 ,  A61P25/00

Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.